Tumor-infiltrating lymphocytes from nonrenal urological malignancies
- 41 Downloads
Tumor-infiltrating lymphocytes (TIL) were isolated from 15 of 20 surgical specimens of transitional cell carcinoma of the urinary bladder, prostate cancer, testicular cancer, Wilms tumor and adrenal cancer. Expansion was carried out in four different culture conditions, each containing 1000 U/ml interleukin-2: RPMI medium with or without 20% (by volume) of lymphokine-activated killer cell (LAK) supernatant and AIM V medium with or without 20% LAK supernatant. The resultant cell populations were then assayed for cytotoxicity against a variety of autologous and allogeneic tumor targets and phenotypic analysis was performed with fluorescein-labeled monoclonal antibodies. TIL growth was unrelated to the initial percentage of lymphocytes or tumor cells present in the enzymatically dispersed specimens or whether fresh or cryopreserved tissue was utilized. Better growth was seen in AIM V than in RPMI medium (P = 0.013); the beneficial effect of the addition of LAK supernatant to RPMI was indicated (P = 0.065), and the addition of LAK supernatant to AIM V did not improve the ability to culture TIL (P = 0.5) from these cancers. TIL in long-term culture were predominantly CD3+. The ratio of CD4+/CD8+ cells varied with time in culture and culture medium, but most cultures eventually became CD4+. Cells bearing B cell, natural killer cell, and macrophage markers disappeared early in culture. Overall 14/15 TIL samples were lytic against one of the autologous and allogeneic targets tested, but specific lysis against the autologous tumor from which it was derived was seen in only one TIL culture originating from a bladder cancer. Our results suggest that TIL can be expanded to therapeutic levels from a variety of urological malignancies and that their potential role in future therapy should be further explored.
KeywordsNatural Killer Cell Transitional Cell Carcinoma Testicular Cancer Autologous Tumor Macrophage Marker
Unable to display preview. Download preview PDF.
- 1.Belldegrun A, Linehan WM, Robertson CN, Rosenberg SA (1986) Isolation and characterization of lymphocytes infiltrating human cancer: possible application for therapeutic adoptive immunotherapy. Surg Forum 37: 671Google Scholar
- 3.Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M (1987) Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumorspecific lymphoproliferative response. J Exp Med 166: 303PubMedGoogle Scholar
- 4.Galili V, Vanky F, Rodriguez L, Klein E (1979) Activated T lymphocytes within human solid tumors. Cancer Immunol Immunotherapy 6: 129Google Scholar
- 5.Haskill S. Some historical prospectives on the relationship between survival and mononuclear cell infiltration. (1982) In: Tumor immunity and prognosis. The Role of Mononuclear Cell Infiltration, Marcel Dekker, New YorkGoogle Scholar
- 16.Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei J, White D (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676PubMedGoogle Scholar
- 18.Topalian SL, Muul LM, Rosenberg SA (1987) Growth and immunologic characteristics of lymphocytes infiltrating human tumor. Surg Forum 37: 390Google Scholar
- 20.Topalian SL, Solomon DL, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6: 839PubMedGoogle Scholar